GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EPIRUS Biopharmaceuticals Inc (OTCPK:EPRSQ) » Definitions » EPS (Diluted)

EPIRUS Biopharmaceuticals (EPIRUS Biopharmaceuticals) EPS (Diluted) : $-2.53 (TTM As of Mar. 2016)


View and export this data going back to 2005. Start your Free Trial

What is EPIRUS Biopharmaceuticals EPS (Diluted)?

EPIRUS Biopharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2016 was $-0.66. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2016 was $-2.53.

EPIRUS Biopharmaceuticals's EPS (Basic) for the three months ended in Mar. 2016 was $-0.66. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2016 was $-2.53.

EPIRUS Biopharmaceuticals's EPS without NRI for the three months ended in Mar. 2016 was $-0.66. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2016 was $-2.57.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


EPIRUS Biopharmaceuticals EPS (Diluted) Historical Data

The historical data trend for EPIRUS Biopharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EPIRUS Biopharmaceuticals EPS (Diluted) Chart

EPIRUS Biopharmaceuticals Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.90 -22.70 -8.83 -6.81 -2.29

EPIRUS Biopharmaceuticals Quarterly Data
Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.39 -0.65 -0.59 -0.63 -0.66

Competitive Comparison of EPIRUS Biopharmaceuticals's EPS (Diluted)

For the Biotechnology subindustry, EPIRUS Biopharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EPIRUS Biopharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EPIRUS Biopharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where EPIRUS Biopharmaceuticals's PE Ratio falls into.



EPIRUS Biopharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

EPIRUS Biopharmaceuticals's Diluted EPS for the fiscal year that ended in Dec. 2015 is calculated as

Diluted EPS (A: Dec. 2015 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-52.188-0)/22.748
=-2.29

EPIRUS Biopharmaceuticals's Diluted EPS for the quarter that ended in Mar. 2016 is calculated as

Diluted EPS (Q: Mar. 2016 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-16.266-0)/24.818
=-0.66

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EPIRUS Biopharmaceuticals  (OTCPK:EPRSQ) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


EPIRUS Biopharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of EPIRUS Biopharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


EPIRUS Biopharmaceuticals (EPIRUS Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
699 Boylston Street, Eighth Floor, Boston, MA, USA, 02116
EPIRUS Biopharmaceuticals Inc is a global biopharmaceutical company focused on building biosimilar business targeting rare diseases by improving patient access through cost-effective medicines. The product candidates of the company are BOW080 for the potential treatment of ultra-rare blood disorders and BOW070 for the potential treatment of an uncommon lymphoproliferative disorder known as Castleman's disease. The group generally operates through the United States.
Executives
Vincent Aurentz officer: Chief Business Officer C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Thomas A. Shea officer: Chief Financial Officer C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET 8TH FLOOR, BOSTON MA 02116
Amit Munshi director, officer: Chief Executive Officer C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Scott M Rocklage director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Julie Mchugh director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Mark Corrigan director
Geoffrey M Duyk director 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Montreux Equity Partners Iv Lp 10 percent owner ONE FERRY BUILDING,, SUITE 255, SAN FRANCISCO CA 94111
5am Ventures Iii, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
5am Co-investors Iii, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Andrew J. Schwab 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
John D Diekman 10 percent owner C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Iii, Llc 10 percent owner 2200 SAND HILL ROAD STE 110, MENLO PARK CA 94025
David Bonderman 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102

EPIRUS Biopharmaceuticals (EPIRUS Biopharmaceuticals) Headlines

From GuruFocus

CEO of Epirus Biopharmaceuticals Buys 10,000 Shares

By Jennifer Chiou Jennifer Chiou 09-23-2015